August 2021 Exhibit 99.2
Certain statements in this presentation and the accompanying oral commentary are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, pipeline and milestones, regulatory objectives, expected payments from and outcomes of collaborations, and likelihood of success, are forward-looking statements. Such statements are predictions only and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, among others, the costs, timing and results of clinical trials and other development activities; the uncertainties inherent in the initiation and enrollment of clinical trials; the uncertainties associated with the COVD-19 pandemic; the unpredictability of the timing and results of regulatory submissions and reviews; market acceptance for approved products and innovative therapeutic treatments; competition; the possible impairment of, inability to obtain and costs of obtaining intellectual property rights; and possible safety or efficacy concerns, general business, financial and accounting risks and litigation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. More information concerning us and such risks and uncertainties is available in our public filings with the U.S. Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and our most recent Annual Report on Form 10-K for the year ended June 30, 2020. We are providing this information as of its date and do not undertake any obligation to update or revise it, whether as a result of new information, future events or circumstances or otherwise, except as required by law. Additional information may be available in press releases or other public announcements and public filings made after the date of this presentation. The Company has filed a registration statement (including a prospectus) and will also file a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) for the offering to which this communication relates, and such registration statement has been declared effective by the SEC. Before you invest, you should read the preliminary prospectus supplement (when available) and the prospectus contained in the registration statement for more complete information about the Company and this offering. The preliminary prospectus supplement (when available) and the registration statement (including the prospectus) may be accessed through the SEC's website at www.sec.gov AVITA Medical’s products are Rx only. Please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events. In the United States, RECELL is approved for use in patients suffering acute thermal burns. Use of RECELL® in other patient populations is either prohibited by United States law or may be made available pursuant to a relevant investigational device exemption granted by the FDA (and likewise limited by United States law to investigational use only). Legal Disclaimers
AVITA Leadership Team Dr. Michael S. Perry CEO >30 years experience Affiliations: Michael Holder CFO >30 years experience Affiliations: Dona Shiroma General Counsel 20 years experience Affiliations: Andrew Quick CTO >25 years experience Affiliations: Kathy McGee COO 25 years experience Affiliations: Erin Liberto CCO 20 years experience Affiliations:
Value Creation Key Accomplishments Projected Key Milestones Japan PMDA Approval EB: Initial proof of concept for delivery of genetically modified cells in suspension Telomerase: Initial proof of concept on impact of telomerase on skin in a mouse model Vitiligo Pivotal Trial Last Patient Enrolled / Vitiligo Commercial launch Outpatient C-Code / TPT FDA Approval of New Ease of Use RECELL Device Last patient enrolled in Soft Tissue Trial / Soft Tissue Commercial Launch Q4 21 H2 21 / H2 23 H2 22 / 24 H1 22 Q1 22 Q4 21 Q4 21 RECELL® commercial revenue growth of +45% vs prior quarter Cumulative U.S. commercial sales since September 2018 FDA approval exceeding $42M (plus $7.6M BARDA Vendor Managed Inventory) Pediatric label expansion FDA Approved New Ease of Use RECELL Device Submitted for FDA Review 77% of Burn Centers VAC Approved Soft Tissue Pivotal Trial - 66% Enrolled FDA Approval of Simplified Vitiligo Pivotal Trial Design Q2 21 Aug 21
One Platform. Endless Possibilities. RECELL enables regeneration of healthy skin Patch of healthy skin removed from patient Healthy skin processed using the RECELL System Autologous skin cells are sprayed on patient RECELL delivers healthy skin cells Free cells modulate and catalyze the healing process Technology platform benefits a wide array of skin defects and wounds irrespective of etiology Vitiligo Burns / Scalds Scar Revision Infectious Disease Regenerative Dermatology Trauma Chronic Wounds Cancer Reconstruction Genodermatoses SKIN RESTORED In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.
Development Pipeline and Growth Potential
Innovation New Device: Improved Ease of Use New Device: Fully Automated INDICATION DISCOVERY FEASIBILITY PIVOTAL APPROVAL Regenerative Therapeutics – Wounds & Dermatology (Current Platform) Acute Thermal Burns (U.S.) RECELL® Japan Vitiligo (U.S.) Soft Tissue Reconstruction (U.S.) Early-Stage Research Programs Epidermolysis Bullosa Rejuvenation Focused Pipeline with Strong Growth Potential In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. CONCEPT DESIGN APPROVAL SUBMISSION Focused Effort on Business Development
CURRENT INDICATION Total Potential Opportunity ~$1.5B Thermal Burns Trauma Vitiligo FUTURE MARKETS ~$750M ~$450M Current Platform Enables Access to a Large Serviceable Market A common goal: Full skin restoration (Re-epithelialization and re-pigmentation) Highly De-risked Pipeline with > 10,000 Patients Treated Globally Efficacy Well Demonstrated Patients (in studies) Publications & Presentations BURNS 1,656 172 DEFECTS/ VITILIGO 435 56 ACUTE WOUNDS 71 24 ~$260M In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.
Thermal Burns: U.S. Target Market Expanded to Include Small Burns and Outpatient Outpatient Pass Thru Code Opens Doors to Small Burns and Expands Serviceable Market Opportunity Total Annual Burns in the U.S. Severe Burns (as defined as burns > 5% Body Surface Area that may require grafting) Target: Severe Burns Treated at Burn Centers (Both In and Outpatient) ~$260 Million SAM >$600 Million TAM Patient Funnel and Addressable Market ~25K ~80K ~486K PATIENTS PATIENTS PATIENTS ($ 000s) Quarter Ended U.S. RECELL Commercial Sales Since Approval
77% Burn Sites Activated 85% Burn Surgeons Certified ~ $42 Million in U.S. RECELL Revenue Since Approval Accomplishments Since Approval ~4,000 Procedures* Strong Adoption of the RECELL System *Data is compiled based on information voluntarily provided by our customers and is subject to change. Procedures* Sites/Surgeons
1. Instructions for Use. RECELL® Autologous Cell Harvesting Device * N = 41, “will significantly or somewhat impact RECELL usage” Fewer procedures required for definitive closure vs conventional autograft1 80% of RECELL Customers Stated that the New Label Enhancements Will Positively Impact Their Usage of RECELL NUMBER OF TREATMENTS NUMBER OF TREATMENTS 3.6 1.6 5.9 2.4 Control RECELL Pediatric Patients 56% fewer mean procedures with RECELL (N=284) Adults with >50% TBSA 60% fewer mean procedures with RECELL (N=354) ~25% of all burns occur in children Now Approved in Pediatric Full-Thicken Burns & Larger TBSAs
March 3, 2019, AVITA Medical and COSMOTEC Company, Ltd, an M3 Group company, announced agreement to market and distribute the RECELL System. COSMOTEC is pursuing a broad indication for use for RECELL in Japan, potentially covering both acute & chronic wounds as well as Vitiligo. RECELL System approval anticipated in Japan in H2 of CY 2021. Japan is the second largest healthcare market in the world. Large patient populations coupled with generally attractive reimbursement coverage makes Japan an attractive market for the RECELL System. Furue M, Yamazaki S, Jimbow K, Tsuchida T, Amagai M, Tanaka T et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multi-center, hospital-based study. J Dermatol. 2011 April; 38(4):310-20 Estimates based on data from 2016 JSBI National Burns Repository and DRG codes - © 2017 Millennium Research Group, Inc. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission Japan Is an Attractive Opportunity for AVITA Medical Burn ~6,000 Patients treated severe burns per year KEY PATIENT POPULATIONS IN JAPAN Vitiligo ~2 million Patients Suffer from Vitiligo Trauma ~22,000 RECELL Eligible Trauma Patients
Vitiligo: Unmet Need, No FDA-Approved Products Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017. Willingness-to-Pay and Quality of Life in Patients with Vitiligo. Radtke, et al. BJD. 2009. SIGNIFICANT UNMENT NEED Up to 2% of the population affected (~6.5M in the US) Vitiligo impacts quality of life (QoL) – 25% of patients with vitiligo reported a DLQI >10, which indicates severe QoL reductions, compared with 34% in psoriasis patients DRUGS AND PHOTOTHERAPY SECOND LINE SURGICAL Medical management For disease stabilization: Cortico-steroids, calcineurin inhibitors 2 treatments per week for 3-6 months Limited efficacy Poor compliance Potential skin atrophy, cancer risk Phototherapy For disease stabilization: UVB, excimer laser 2-3 treatments / week for a few months to over a year Typically combined with topicals Not durable Skin grafting For repigmentation of stable lesions (rarely performed): Punch & suction blister grafting Transplantation of small sections of pigmented skin to depigmented areas Melanocyte-keratinocyte transplantation For repigmentation of stable lesions: Requires substantial laboratory equipment Combination PUVA (psoralen with phototherapy) No FDA-approved medical treatments; extremely low patient and physician satisfaction with existing products LIMITED TREATMENT OPTIONS Note: Surgical approaches are performed very rarely and only at very specialized academic centers In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.
Blinded, Randomized, Study Evaluating RECELL for Repigmentation of Stable Vitiligo in 23 Patients New Vitiligo Study Design Shortens Pathway to Completion In the United States, RECELL is not approved for use with patients suffering vitiligo. POTENTIAL RECELL BENEFITS AT 6 MONTHS RECELL-treated area was 100% re-pigmented RECELL treated Negative Control U.S. Pivotal Study enrolling; last patient expected in H2 2021 For Stable Vitiligo of All Types: Segmental & Non-Segmental Complementary to Existing Products & those in Development Durable: One-time treatment to regenerate pigmentation •New design focuses on 1:20 donor expansion, using less donor skin for treatment vs prior study which also included 1:10 and 1:5 expansion New design reduces subject requirements to 23 vs prior 3-arm design which required 84 subjects 15 clinical sites are already active and able to enroll subjects. Each site is required to treat a run-in training subject. •Ongoing traditional and social media outreach campaigns along with local clinic referral programs are providing a strong pipeline of candidate subjects Assessment and Therapy of Vitiligo, Lisa Komen, 2015
Yu et al. Repigmentation of nipple-areola complex after RECELL® treatment on breast vitiligo. Journal of Cosmetic Dermatology, 2021 RECELL Case Study: Repigmentation of the Nipple-Areola Complex after Breast Treatment Established Track Record in Vitiligo: 1,000 patients treated internationally & 12 peer reviewed publications showing positive outcomes 23 year old female with vitiligo. Donor skin was harvested from adjacent unaffected areas. Dermabrasion of the vitiligo patches was performed to the depth of the dermal-epidermal junction. The cellular suspension was then sprayed on both the recipient and donor areas (expansion ratio ranged from 1:20-1:40). Before RECELL® 12 months After RECELL® In the United States, RECELL is not approved for use with patients suffering vitiligo.
Significant Market Opportunity in Repigmenting Stable Vitiligo OPPORTUNITY ESTIMATION MARKET TAILWINDS Concentrated HCP base: Estimating <1,000 procedural dermatologists and plastic surgeons with interest in treating vitiligo SAM $750 Million TAM $5.2 Billion 4.5M (range 3-6.5 million) TOTAL MARKET 1.3M TOTAL ADDRESSABLE MARKET SERVICEABLE AVAILABLE MARKET 188K Estimated number of eligible patients at target call points Patients with Stable Vitiligo, eligible for surgical treatment Prevalence of Vitiligo in the United States Advancing pipeline of disease stabilizing treatments JAK inhibitors are in late-stage development. Potential to help build market and expand eligible patients Growing reimbursement (up to $38,000 / patient annually) Increasing treatment-seeking behavior Payers with coverage for vitiligo treatments (e.g., phototherapy) Not exhaustive Number of patients seeking treatment in 2013 150k Number of patients seeking treatment in 2019 300k In the United States, RECELL is not approved for use with patients suffering vitiligo.
COVID19 IMPACT Soft Tissue Reconstruction Trial Enrollment is Gaining Momentum Sites Initiated N=65 Patients Enrolled Patients Enrolled Sites initiated TREATMENT DAY Patient treated for necrotizing fasciitis. 1 YEAR POST-RECELL TREATMENT Clinical trial demonstrates use of less donor skin without compromising healing outcomes relative to conventional autografting In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.
Soft Tissue Repair: Synergistic with Current Commercial Focus >4.5M patients TOTAL MARKET >140K TOTAL ADDRESSABLE MARKET SERVICEABLE AVAILABLE MARKET >65K patients patients RECELL eligible procedures at high volume sites RECELL eligible trauma procedures OPPORTUNITY ESTIMATION SAM $450 Million TAM $1 Billion Open wounds presented at the Emergency Department In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. In the United States, RECELL is not approved for use in pediatrics. Use of RECELL in this case was performed internationally where the indication is approved. Same Treatment Protocol to Burns Consistent treatment protocol across acute injuries Same Unmet Needs as Burns Reduction of donor site morbidity & donor site requirements are top unmet needs Reimbursement in Place Able to leverage existing CPT & outpatient codes Burns Field Team Can be Leveraged for Quick Entry into Existing Accounts ~50% of Current Targets are Level 1/Level 2 Trauma Accounts 136 Burn Centers (Current Target) +230 High Volume Trauma Centers (Future Expansion) Future Target: 366 Total Centers
RECELL in Genetic Skin Defects and Rejuvenation CURRENT PLATFORM FUTURE PLATFORM Treatment using RECELL for harvesting and direct reintroduction of the patient’s own healthy skin cells RECELL as a platform for treatment using the patient’s corrected skin cells Patch of healthy skin removed from patient Healthy skin processed using the RECELL System Autologous skin cells are sprayed on patient Skin processed using the RECELL System Patch of skin removed from patient Enhanced autologous skin cells are reintroduced to patient Gene editing for debilitating orphan skin disorder Molecular reversal of aging for skin rejuvenation Skin cells are genetically modified In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.
Exploring Cell-Based Gene Therapy for Epidermolysis Bullosa In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. THE CHALLENGE THE OPPORTUNITY DEBILITATING Skin fragility, disability, cancer HIGH UNMET NEED No FDA-approved treatment, only palliative measures COST BURDEN Care of $200K-$500K per year per patient Proof-of-concept for delivering genetically modified cells in suspension expected in 2021 Preclinical research partnership underway, exploring the combination of a novel gene correction approach with AVITA Medical’s Spray-On SkinTM Cells technology AVITA AND GATES CENTER COLLABORATION COMPETITOR PIPELINE PROGRAMS Technology for precise correction of genetic defect & banking for future use Majority focused on ameliorating symptoms, or based on foreign DNA insertion, which could have negative long-term effects CURATIVE Suspension-based approach eliminates growth & transport of skin sheets Some competitors focused on growth of gene-edited skin sheets, which suffer from fragility EFFICIENT Suspension-based product simplifies application onto patient wounds Epidermal sheets require surgical anchoring and can result in complex procedures and issues with 'take rates' CONVENIENT
Patented RNA technology for delivery of telomerase enzyme to aged cells Demonstrated reversal of aging and return of functionality in cells of progeria patients (human model of accelerated aging) Patented and proprietary Spray-On Skin Cells technology and device (RECELL) Expertise in skin regeneration, including in preclinical models Strong track record and expertise in clinical development and commercialization Exploring Novel RNA-Based Approach for Rejuvenation Multi-Billion Dollar Market Presents a Sizeable Opportunity >$16.5B spent in aesthetic procedures per year (US)* >3M aesthetic procedures per year (US) aimed to improve skin tightness, texture & evenness in skin tone* Consumers desire superior results over current offerings Personalized, cellular-level approaches to skin rejuvenation, developed with robust evidence, is an area of significant interest *American Society for Plastic Surgery Annual reports – 2018 and 2019. 2. Goddard et al. Aesthetic Surgery Journal, Volume 40, Issue 4, April 2020, Pages 460–465. In the U.S., RECELL is approved for acute thermal burns in patients > 18 years. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited. Sponsored research underway exploring use of telomerase for molecular reversal of skin cell aging
Corporate
12 Months Ended June 30 (USD in $000s) 2018 2019 2020 2021 Commercial Sales 929 5,474 14,263 21,483 BARDA Sales - - - 7,749 Total Revenue 929 5,474 14,263 29,232 Gross Profit 383 4,203 11,290 23,283 BARDA Income 7,734 5,921 3,926 2,055 Cash 10,986 20,174 73,639 110,746 $18.43 Share Price1 Financial Overview 1. RCEL as 8/24/2021 $459 Million Market Capitalization1 $0.0 (Zero) Debt Nasdaq ticker symbol: RCEL ASX ticker symbol: AVH Analysts Matt O'Brien, Piper (U.S.) Josh Jennings, Cowen (U.S.) Ryan Zimmerman, BTIG (U.S.) Chris Kallos, MST (AUS) John Hester, Bell Potter (AUS) Shane Storey, Wilsons (AUS) Brooks O’Neil, Lake Street (U.S.) Lyanne Harrison, BofA Global Research (AUS) Nicolette Quinn, MorningStar (AUS)
A Global Total of 56 Granted Patents & 26 Pending Applications Note: AVITA Medical owns granted patents in Austria, Australia, Belgium, Brazil, France, Germany, Hong Kong, Italy, Japan, Netherlands, Portugal, Spain, Sweden, Turkey, United Kingdom and USA. AVITA Medical owns pending patent applications in Brazil, Canada, China, Europe, Hong Kong and USA. Patent count as of 6/30/2021 ROBUST PROTECTION ACROSS PATENT FAMILIES EXPANDING PORTFOLIO TO SUPPORT CURRENT AND FUTURE INDICATIONS Next Generation RECELL devices to improve ease of use in burns and pipeline indications Potential to license patented technology for telomerase mRNA that has the potential to reverse aging of skin cells Potential to license technologies for suspension-based delivery of genetically modified cells, with applications to genetic skin disorders Commercial RECELL device, composition of matter, and associated methods of use Cell Suspension Preparation Technique and Use Method of preparing cell suspension with exogenous agent to promote wound healing Cell Suspension And Use Thereof Automated system for preparing cell suspension and method of production Systems and Methods for Tissue Processing and Preparation of Cell Suspension Therefrom Robust and Expanding Patent Estate: Expiration from 2022 to 2040 All-in-one RECELL kit, system, and associated method of use Devices, Methods, and Kits for Preparing a Cell Suspension Method and system for validating the use of a cell suspension for administration to a patient Methods for Identifying Cell Suspensions with Therapeutic Potential for Skin Regeneration Bioactive suspension derived from freshly disaggregated tissue, and associated methods of preparation and use Bioactive Therapeutic Suspensions with Cellular-Based Supernatant
Value Creation Key Accomplishments Projected Key Milestones Japan PMDA Approval EB: Initial proof of concept for delivery of genetically modified cells in suspension Telomerase: Initial proof of concept on impact of telomerase on skin in a mouse model Vitiligo Pivotal Trial Last Patient Enrolled / Vitiligo Commercial launch Outpatient C-Code / TPT FDA Approval of New Ease of Use RECELL Device Last patient enrolled in Soft Tissue Trial / Soft Tissue Commercial Launch Q4 21 H2 21 / H2 23 H2 22 / 24 H1 22 Q1 22 Q4 21 Q4 21 RECELL® commercial revenue growth of +45% vs prior quarter Cumulative U.S. commercial sales since September 2018 FDA approval exceeding $42M (plus $7.6M BARDA Vendor Managed Inventory) Pediatric label expansion FDA Approved New Ease of Use RECELL Device Submitted for FDA Review 77% of Burn Centers VAC Approved Soft Tissue Pivotal Trial - 66% Enrolled FDA Approval of Simplified Vitiligo Pivotal Trial Design Q2 21 Aug 21
Revolutionary treatment using a patient’s own skin for life-changing outcomes In the U.S., RECELL is approved for acute thermal burns. Use of RECELL in other indications is either (1) limited by United States law to investigational use; or (2) otherwise prohibited.
There are numerous risk factors involved with the Company’s business. Some of these risks can be mitigated by the use of safeguards and appropriate systems and controls, but some are outside the control of the Company and cannot be mitigated. Accordingly, an investment in the Company carries no guarantee with respect to the payment of dividends, return of capital or price at which securities will trade. The following is a summary of the more material matters to be considered. However, this summary is not exhaustive. Potential investor should consult their professional advisors before deciding whether to invest. Technological Change: Technological change presents the Company with significant opportunities for growth. However, the risk remains that any competitor may introduce new technology enabling it to gain a significant competitive advantage over the Company. Reliance on key personnel: The Company's success depends to a significant extent upon its key management personnel, as well as other management and technical personnel including sub-contractors. The loss of the services of any such personnel could have an adverse effect on the Company. Competition: The Company competes with other companies, including nationally in Australia and internationally. Some of these companies have greater financial and other resources than the Company and, as a result, may be in a better position to compete for future business opportunities. There can be no assurance that the Company can compete effectively with these companies. Patent Protection: The patent protection that the Company may obtain varies from product to product and country to country and may not be sufficient, including to maintain product exclusivity. Patent rights are also limited in time and do not always provide effective protection for products and services: competitors may successfully avoid patents through design innovation, the Company may not hold sufficient evidence of infringement to bring suit, or the infringement claim may not result in a decision that the rights are valid, enforceable or infringed. Legislation or regulatory actions subsequent to the filing date of a patent application may affect what an applicant is entitled to claim in a pending application and may also affect whether a granted patent can be enforced in certain circumstances. Laws relating to biotechnology remain the subject of ongoing political controversy in some countries. The risk of changed laws affecting patent rights is generally considered greater for the biotechnology field than in other longer established fields. Change in government policy and legislation: Any material adverse changes in relevant government policies or legislation of Australia / United States may affect the viability and profitability of the Company, and consequent returns to investors. The activities of the Company are subject to various federal, state and local laws governing prospecting, development, production, taxes, labor standards and occupational health and safety, and other matters. Risk Factors and Disclosures
INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds. The RECELL device is used by an appropriately-licensed healthcare professional at the patient’s point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. . CONTRAINDICATIONS: RECELL is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann’s) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions. WARNINGS: Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL Enzyme is animal derived and freedom from infectious agents cannot be guaranteed. PRECAUTIONS: RECELL is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, and in patients younger than 28 days of age (neonates). SPECIAL PATIENT POPULATIONS: The safety and effectiveness of RECELL have not been established for treatment of acute thermal partial-thickness burn wounds in pediatric patients younger than 18 years of age. Important Safety Information
